Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.04 below Hcw Biologics Inc 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 434 other companies have achieved higher Quick Ratio than Hcw Biologics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 4079, from total ranking in the first quarter 2026 at 4126.

Explain Quick Ratio?
How much Cash & cash equivalents HCWB�s has?
What are HCWB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HCWB/financial-strength

https://api.csimarket.com/api/v1/companies/HCWB/fundamentals

https://api.csimarket.com/api/v1/companies/HCWB/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

HCWB Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-30.54 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-69.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.04	Subscribe	Subscribe	Subscribe	Subscribe
HCWB's Total Ranking	# 4079	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-6.57 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-39.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 435
Healthcare Sector	# 882
Overall Market	# 4125

Quick Ratio Statistics
High	Average	Low
54.45	8.06	0.03
(Dec 31 2020)

Financial Statements
Hcw Biologics Inc 's Current Liabilities	$ 19 Millions	Visit HCWB's Balance sheet
Hcw Biologics Inc 's Cash & cash equivalent	$ 1 Millions	Visit HCWB's Balance sheet
Source of HCWB's Sales		Visit HCWB's Sales by Geography

Cumulative Hcw Biologics Inc 's Quick Ratio

HCWB's Quick Ratio for the trailling 12 Months

HCWB Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-52.36 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-45.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.09	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4157	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-13.15 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-25.27 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to HCWB Financial Strength Comparisons >> Go to Compare HCWB Quick Ratio to its Competitors

News about Hcw Biologics Inc Quick Ratio

Innovations in T-Cell Engagement HCW Biologics Unveils Preclinical Data at SITC 40th Annual Meeting

In the rapidly evolving field of immunotherapy, HCW Biologics Inc. has made significant strides with the presentation of groundbreaking preclinical data for its tetra-valent T-cell engager programme at the Society for Immunotherapy of Cancers’ (SITC) 40th Annual Meeting. This latest development showcases the promising potential of HCW Biologics novel approach to T-cell engagement, designed to overcome inherent limitations associated with existing bi-specific T-cell engagers (BiTEs).The tetra-valent T-cell engager stands out for its innovative design, specifically targeting the shortfalls characteristic of traditional BiTEs. These shortcomings often relate to two main areas: manufacturability and safety profile, particularly in the treatment of a diverse range of solid tumours. By introducing a multi-valent format, HCW Biologics aims to enhance the efficacy and safety of T-cell engagement, paving the way for more potent therapeutic interventions in oncology. The company s focus on solid tumours is particularly relevant in the context of modern cancer treatment, where the versatility and effectiveness of therapies are crucial in achieving positive patient outcomes.

On the trailing twelve months basis In spite of the year on year decrease in HCWB's Current Liabilities to $18.65 millions, cumulative Quick Ratio to 0.09 below the HCWB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Hcw Biologics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3021 to 4157.

Explain Quick Ratio?
How much Cash & cash equivalents HCWB�s has?
What are HCWB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 917
Within the Market	# 4157

trailing twelve months Quick Ratio Statistics
High	Average	Low
19.83	5.4	0.06
(Jun 30 2022)		(Jun 30 2026)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Igc Pharma Inc	0.11	$ 0.354 Millions	$ 3.287 Millions
Tuhura Biosciences Inc	0.11	$ 0.996 Millions	$ 9.255 Millions
Gridai Technologies Corp	0.10	$ 1.380 Millions	$ 14.146 Millions
Bioxcel Therapeutics Inc	0.09	$ 12.841 Millions	$ 137.149 Millions
Lunai Bioworks Inc	0.09	$ 1.714 Millions	$ 18.910 Millions
Galectin Therapeutics Inc	0.09	$ 13.275 Millions	$ 151.619 Millions
Lftd Partners Inc	0.08	$ 0.304 Millions	$ 3.648 Millions
Processa Pharmaceuticals Inc	0.08	$ 0.196 Millions	$ 2.387 Millions
Vogenx, Inc.	0.06	$ 0.193 Millions	$ 3.188 Millions
Cv Sciences Inc	0.05	$ 0.266 Millions	$ 4.943 Millions
Citius Pharmaceuticals Inc	0.05	$ 17.008 Millions	$ 333.952 Millions
Sunshine Biopharma Inc	0.05	$ 0.281 Millions	$ 5.619 Millions
Hcw Biologics Inc	0.04	$ 0.741 Millions	$ 18.648 Millions
China Pharma Holdings Inc	0.04	$ 0.305 Millions	$ 7.682 Millions
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
Celularity Inc	0.01	$ 0.586 Millions	$ 59.738 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.